TMEM183A

Across TCGA pan-cancer cohorts, TMEM183A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMEM183A data layer compared with 21 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TMEM183A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM183A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, UCEC, and PRAD are the cancer types where TMEM183A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
UCEC	DFS	Median	II,III,IV	1.000	0.485	.030	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TMEM183A–LIHC (OS)

Open the LIHC breakdown →